期刊文献+

扶正为主辨治晚期非小细胞肺癌的疗效研究 被引量:5

Clinical Research on Therapeutic Effect of Strengthening Body Resistance TCM Consolidated Therapy for Advanced Non-Small-Cell Lung Cancer
暂未订购
导出
摘要 目的:观察扶正为主辨证论治对晚期非小细胞肺癌(NSCLC)的疗效。方法:采用前瞻性、随机设计研究方法。选取晚期NSCLC一线治疗后疾病无进展的患者,随机分为治疗组和对照组各29例,治疗组以扶正为主辨证论治进行巩固治疗,对照组不进行中药抗肿瘤治疗。每月随访1次,治疗直至疾病进展或患者拒绝治疗为止。观察扶正为主辨证论治对晚期NSCLC一线化疗后疾病控制患者巩固治疗的临床疗效。观察指标包括疾病进展时间(Time to Progression,TTP)、中医症状改善情况、体重变化、生活质量(Quality of Life,QOL)。结果:(1)治疗组中位TTP为89 d,对照组中位TTP为70 d,差异有统计学意义(P<0.05);(2)治疗组患者中医症状积分明显改善,总有效率86.21%较对照组的17.24%,差异有统计学意义(P<0.05);(3)治疗组体重稳定率79.31%较对照组的44.83%,差异有统计学意义(P<0.05);(4)扶正为主辨证论治能明显改善晚期NSCLC患者的生活质量,EORTC QLQ-LC43中的躯体、角色、情绪、社会功能领域,总健康状况,疲倦、恶心呕吐、气促、失眠、食欲丧失、便秘、咳嗽、口腔溃疡、脱发的症状领域方面较对照组都有明显改善,差异均有统计学意义(P<0.05)。结论:(1)中医巩固治疗对晚期非小细胞肺癌一线化疗疾病控制后患者能延长疾病进展时间;(2)中医巩固治疗能明显改善晚期非小细胞肺癌患者一线化疗后中医症状和稳定体重;(3)中医巩固治疗能提高晚期非小细胞肺癌患者一线化疗后生活质量。 Objective: To observe the therapeutic effect of strengthening the body resistance consolidated therapy for advanced non-small-cell lung cancer. Methods: The study was a prospective, multicenter and randomized clinical trial. Non-progressive ( CR/ PR/SD) patiants with advanced non-small-cell lung cancer who responded to first-line therapy were radomized into the treatment group and the control group. All patients were divieded with the sealed envelope method in the ratio. There are twenty nine cases in each group. The treatment group was treated with TCM consolidated therapy. The control group was not treated with TCM antineoplastic thera- py. All cases were follow up once a month. Treatment were not over until the appearances of disease progression or rejection of pa-tients. To oberserve the therapeutic effect of TCM consolidated therapy for the disease control patients with advanced non-small-cell lung cancer. The observe gauge including Time to Progression (TTP) , TCM symptoms integral improvement, weight, and Quality of Life (QOL) . Results: (1) The middle TIP in the treatment group was prolonged for 19 days when compared with that of the control group, the difference was statistically significant (89 days versus 70 days, P 〈 0. 05 ) . (2) The TCM symptoms integral of the treatment group patients obviously improved, with the total effective rate was 86.21%. The total effective rate of the control group was 17.24%. The difference was statistically significant (P 〈0.05) . (3) The weight stability rate of the treatment group patients was 79. 31% better than 44. 83% that of the control group, traditional Chinese medicine can obviously improve the weight stability rate of patients (P 〈0.05) . (4) TCM can obviously improve the QOL of the NSCLC patients. The scores of the treatment group in EORTC QLQ-LC43 were better than that of the contrl group with statisticallly significant difference (P 〈 0. 05), including the role, mood, social areas, total health, fatigue, nausea and vomiting, shortness of breath, insomnia, loss of appetite, constipation, cough, oral ulcer, the symptoms of hair loss. Conclusion: ( 1 ) TCM consolidated treatment can extend TIP of the disease control patients with advanced non-small-cell lung cancer. (2) TCM consolidated treatment can improve the TCM symptoms and stabilize weight of the dis- ease control patients with advanced non-small-cell lung cancer. (3) TCM consolidated treatment can improve the quality of life of the disease control patients with advanced non-small-cell lung cancer.
出处 《成都中医药大学学报》 2014年第2期76-79,85,共5页 Journal of Chengdu University of Traditional Chinese Medicine
基金 上海市卫生局中医药科研基金项目(编号:2010L012A)
关键词 扶正 非小细胞肺癌 巩固治疗 中医药 Strengthening the body resistance non-small-cell lung cancer consolidated therapy traditional Chinese medicine.
  • 相关文献

参考文献4

  • 1亓凤丽.吸烟致肺癌分子机制的研究进展[J].预防医学情报杂志,2004,20(3):270-272. 被引量:11
  • 2NCCN中国版专家组.2011NCCN非小细胞肺癌临床实践指南中国版[S].第一版.2011年:MS1-3.
  • 3Pfister DG, Johnson DH, Azzoli CG, et al. American So- ciety of Clinical Oncology treatment of unresectable non- small-cell lung cancer guideline [ J ]. J Clin Oncol, 2004, 22: 330-353.
  • 4中国抗癌协会.新编常见恶性肿瘤诊治规范第九分册[M].北京:中国协和医科大学出版社,1997:737-781.

二级参考文献14

  • 1黄克武.吸烟致肺癌的基因基础[J].国外医学(呼吸系统分册),1996,16(4):169-171. 被引量:8
  • 2World Health Organization. Tobacco or health: a global status report. Geneva: WHO. 1997: 10-48.
  • 3Robles AL, Linke SP, Harris CC. The p53 network in lung carcinogenesis [J]. Oncogene, 2002, 21: 6898-6907.
  • 4Brownson RC, Figgs LW, Caisley LE. Epidemiology of environmental tobacco smoke exposure [J]. Oncogene,2002, 21, 7341-7348.
  • 5Rojas M, Cascorbi I, Alexandrov K, et al. Modulation of benzo [a] pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism [J]. Carcinogenesis, 2000, 21(1): 35 - 41.
  • 6Osada H. Takahashi T. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progresion of lung cancer [J]. Oncogene, 2002, 21: 7421-7434.
  • 7Pfeifer G P, Denisenko M F, Oliver M, et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers [J]. Oncogene2002, 21:7435- 7451.
  • 8Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention [J]. Lancet Oncol, 2002, 3: 461-469.
  • 9Hoffmann D, Hecht S. Handbook of experimental pharmacology, 94/led. Cooper CS and Grover PL [M]. Heidelberg: Springer-Verlag. 1990: 63-102.
  • 10Hoffmann D, Hoffmann I, EI-Bayoumy K. The less harmful cigarette: a controversial issue a tribute to Ernst L.Wynder [J]. Chem Res Toxicol, 2001 - 14 (7): 767 -790.

共引文献17

同被引文献76

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1831
  • 2徐振晔,金长娟,沈德义,李敏,周卫东,朱晏伟,张铭,邓海滨,王中奇,李蕾,寿伟臻,郑展.中医药分阶段结合化疗治疗晚期非小细胞肺癌的临床研究[J].中国中西医结合杂志,2007,27(10):874-878. 被引量:65
  • 3Boukovinas I,Kosmidis P.Treatment of non-small cell lung cancer patients with performance status2(PS2)[J].Lung Cancer,2009,63(11):10-15.
  • 4Frances A,Shepher D,Jean-Yves D,et al.Immunotherapy for Non-small Cell Lung Cancer[J].Chin J Lung Cancer,2013,16(4):C9-C19.
  • 5Park H,Li Z,Yang XO,et al.A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17[J].Nat Immunol,2005,6(11):1133-1173.
  • 6Bettelli E,Carrier Y,Gao W,et al.Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells[J].Nature,2006,441(7090):235-242.
  • 7Zhao ZR,Zhang LJ,Wang YY,et al.Increased serum level of Nup88 protein is associated with the development of colorectal cancer[J].Med Oncol,2012,29(3):1789-1795.
  • 8Jimenez CR,Knol JC,Meijer GA,et al.Proteomics of colorectal cancer:overview of discovery studies and identification of commonly identified cancer-ass ociated proteins and candidate CRC serum markers[J].J Proteomics,2010,73(10):1873-1895.
  • 9Cross MJ,Claesson Welsh L.FGF and VEGF function in angiogenesis:signalling pathways,biological responses and therapeutic inhibition[J].Trends Pharmacol Sci,2001,22(4):201-207.
  • 10Karamysheva AF.Mechanisms of angiogenesis[J].Biochemistry(Moscow),2008,73(7):751-762.

引证文献5

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部